Outcomes of Eyes Lost to Follow-Up in Patients with Central Retinal Vein Occlusion Who are Receiving Anti-Vascular Endothelial Growth Factor Treatment

Kaibo Yang, Lei Liu, Hao Feng, Jun Li, Zheli Liu, Henan Liu, Han ZhangTherapeutics 2021 · DOI

Abstract

In CRVO-ME patients who are receiving anti-VEGF therapy, unintentional treatment interruptions can cause visually disastrous consequences, including irreversible blindness. Patients who were LTFU for a long period should be strongly warned about their poor visual prognosis.
BibTeX
@inproceedings{yang2021outcomes,
  author = {Kaibo Yang and Lei Liu and Hao Feng and Jun Li and Zheli Liu and Henan Liu and Han Zhang},
  title = {{Outcomes of Eyes Lost to Follow-Up in Patients with Central Retinal Vein Occlusion Who are Receiving Anti-Vascular Endothelial Growth Factor Treatment}},
  booktitle = {Therapeutics},
  year = {2021},
  doi = {10.2147/tcrm.s303248},
}

Loading related content...

Figure